Hosted on MSN6h
Oppenheimer Upgrades BioMarin Pharmaceutical (BMRN)Fintel reports that on February 24, 2025, Oppenheimer upgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) from ...
Oppenheimer upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a market perform rating to an outperform rating in a research note published on Monday morning, MarketBeat ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...
BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set ...
StockStory.org on MSN4d
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up TodayShares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company ...
StockStory.org on MSN6d
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 EarningsBiotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to ...
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback